News

RP104 is a proprietary delayed-release tablet formulation of cysteamine bitartrate, used as a treatment option for non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD)

The results demonstrated that GR-MD-02 reversed fibrosis in mouse models of steatohepatitis and prevented collagen deposits in groups treated before fibrotic cells were present. The study also suggests

The DataLabs EDC solution is believed to simplify workflows and streamline the process from study design to data collection, management, and reporting. The solution is offered as a

The transaction covers Dermik assets comprising an aesthetic and therapeutic business in the US and Canada, as well as an aesthetic business worldwide. Sanofi’s Laval, Canada site, which

PureTrim Truffles, which is chocolate flavored, is believed to help people to stay on track during their weight loss routines. The product made from organic ingredients is free

Vernalis is entitled to receive a payment of £0.4m from Lundbeck and the collaboration will now advance into its third stage. Vernalis will receive fees and a potential

The funding comprises $750,000 from the Muscular Dystrophy Association (MDA), $250,000 from Parent Project Muscular Dystrophy (PPMD) and $500,000 from a group of four independent Duchenne foundations spanning

Under future technical and commercial agreements, Angel will utilize its GMP facility at Cramlington to expedite and optimize the expression systems provided by TransGenRx. TransGenRx chief scientific officer

Sygnature and Cyprotex will extend their collaborative sales and marketing initiative to provide discovery chemistry/ADME-Tox/DMPK service to accelerate their clients’ drug discovery projects into development. Cyprotex CEO Anthony